# Efficacy of Asciminib in Real-world in Patients With Chronic Myeloid Leukemia in Second or Subsequent Lines

> **NCT07640750** · — · NOT_YET_RECRUITING · sponsor: **Gruppo Italiano Malattie EMatologiche dell'Adulto** · enrollment: 98 (estimated)

## Conditions studied

- Chronic Myeloid Leukemia
- Chronic Myeloid Leukemia - Chronic Phase

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT07640750
- **Lead sponsor:** Gruppo Italiano Malattie EMatologiche dell'Adulto
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09-01
- **Primary completion:** 2031-09-01
- **Final completion:** 2031-12-01
- **Target enrollment:** 98 (ESTIMATED)
- **Last updated:** 2026-06-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07640750

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07640750, "Efficacy of Asciminib in Real-world in Patients With Chronic Myeloid Leukemia in Second or Subsequent Lines". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07640750. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*